Febuxostat ( DrugBank: Febuxostat )

3 diseases

ID	Disease name (Link within this page)	Number of trials
2	Amyotrophic lateral sclerosis	2
6	Parkinson disease	3
13	Multiple sclerosis/Neuromyelitis optica	1

2. Amyotrophic lateral sclerosis

Clinical trials : 645 / Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000029308	2017/07/18	30/09/2018	Study on efficacy and safety as well as on the changes in blood purine compounds by the treatment of ...	Study on efficacy and safety as well as on the changes in blood purine compounds by the treatment of ...	Amyotrophic lateral sclerosis	Febuxostat 20 mg, Inosine 500 mg, twice a day for 14 days	Teikyo University	NULL	Complete: follow-up complete	20years-old	80years-old	Male and Female	3	Not applicable	Japan
2	JPRN-UMIN000024312	2016/09/20	25/05/2017	Studies of efficacy and safety of the combined use of febuxostatand inosine for patients with Alzhei ...	Studies of efficacy and safety of the combined use of febuxostatand inosine for patients with Alzhei ...	Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or multiple sclerosis	Treatment with febuxostat 20 mg and inosine 0.5 g, twice a day for 2 weeks	Tsukuba International Clinical Pharmacology Clinic	NULL	Complete: follow-up complete	20years-old	80years-old	Male and Female	12	Not selected	Japan

First Previous1Next Last

6. Parkinson disease

Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

diseases per page:

Showing 1 to 3 of 3 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCTs031190115	11/10/2019	11/10/2019	PK & PD of coadministration of XOR inhibitor and inosine	Pharmacokinetics and pharmacodynamics study of coadministration of either allopurinol or febuxostata ...	Parkinson's disease neurodegenerative disease	Coadministration of allopurinol and inosine, or coadministration of febuxostat and inosine	Kamatani Naoyuki	NULL	Complete	>= 20age old	<= 40age old	Male	28	Phase 1	Japan
2	JPRN-UMIN000030930	2018/01/29	01/01/2019	Study on efficacy and safety of the simultaneous treatment with febuxostatand inosine of patients wi ...	Study on efficacy and safety of the simultaneous treatment with febuxostatand inosine of patients wi ...	Parkinson's disease	Administration of febuxostat 20 mg and inosine 500 mg twice a day for 58 days	StaGen Co. Ltd.	NULL	Complete: follow-up complete	20years-old	80years-old	Male and Female	30	Not selected	Japan
3	JPRN-UMIN000024312	2016/09/20	25/05/2017	Studies of efficacy and safety of the combined use of febuxostatand inosine for patients with Alzhei ...	Studies of efficacy and safety of the combined use of febuxostatand inosine for patients with Alzhei ...	Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or multiple sclerosis	Treatment with febuxostat 20 mg and inosine 0.5 g, twice a day for 2 weeks	Tsukuba International Clinical Pharmacology Clinic	NULL	Complete: follow-up complete	20years-old	80years-old	Male and Female	12	Not selected	Japan

First Previous1Next Last

13. Multiple sclerosis/Neuromyelitis optica

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000024312	2016/09/20	25/05/2017	Studies of efficacy and safety of the combined use of febuxostatand inosine for patients with Alzhei ...	Studies of efficacy and safety of the combined use of febuxostatand inosine for patients with Alzhei ...	Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or multiple sclerosis	Treatment with febuxostat 20 mg and inosine 0.5 g, twice a day for 2 weeks	Tsukuba International Clinical Pharmacology Clinic	NULL	Complete: follow-up complete	20years-old	80years-old	Male and Female	12	Not selected	Japan

First Previous1Next Last